Island Pharmaceuticals Ltd · ASX:ILA

Island Pharmaceuticals — Investor Presentation (December 2022)

12 slides from Island Pharmaceuticals's investor presentation, Dec 15, 2022

  1. Slide 1: Solving Urgent Viral Disease Threats

    For personal use only SOLVING URGENT VIRAL DISEASE THREATS (ASX: ILA) Online investor briefing December 2022 ISLAND PHARMACEUTICALS LIMITED 1 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited should not be relied upon as (and is not) an indication of the Company's earnings, capital expenditure, cash flow and capital structure risks and For personal use only (ABN 641 183 842) (Company or Island Pharmaceutical

  3. Slide 3: Mid clinical-stage drug repurposing company focused on antivirals

    For personal use only Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases ISLAND PHARMACEUTICALS LIMITED 3 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021

  4. Slide 4: Island at a Glance

    ISLAND AT A GLANCE For personal use only Advancing lead drug Dengue infects +390 million year Major market ISLA-101 toward Phase 2 No current pharmaceutical treatment potential “PEACH”* clinical trial for the for the disease. Limited access to only In mosquito-borne prevention of dengue fever. one v

  5. Slide 5: Dengue fever is the most rapidly spreading mosquito-borne virus infection

    For personal use only “DENGUE FEVER IS THE MOST RAPIDLY SPREADING MOSQUITO-BORNE VIRUS INFECTION IN THE WORLD.” World Health Organisation, 13 October 2022 ISLAND PHARMACEUTICALS LIMITED 5 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021

  6. Slide 6: Mosquito Borne Viruses: Global Challenges

    MOSQUITO BORNE VIRUSES: GLOBAL CHALLENGES For personal use only Nov 23, 2021 https://www.straitstimes.com/singapore/health/more-than-30000-dengue-cases-reported-in-2022-6-times-that-of-2021-nea ISLAND PHARMACEUTICALS LIMITED Investor Presentation – October2022 2021 https://www.australiangeographic.c

  7. Slide 7: IND Submission Imminent

    IND SUBMISSION IMMINENT IND IS THE LAST STEP, ENABLING PEACH STUDY COMMENCEMENT For personal use only Sponsor information (complete) Drug manufacturing Summary of existing (complete) human data (complete)  Drug substance (API)  ~45 previous clinical  Drug product trials  Human safety data Trial

  8. Slide 8: Manufacturing Now Complete

    MANUFACTURING NOW COMPLETE For personal use only Manufactured capsules Stability now achieved being processed on packaged drug product ISLAND PHARMACEUTICALS LIMITED 8 Investor INVESTOR Presentation PRESENTATION – October2022 – DECEMBER 2021

  9. Slide 9: Phase II Dengue (PEACH) Trial Study in Detail

    PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL “PEACH" STUDY- A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY FOR THE PROPHYLACTIC EXAMINATION OF AN ANTIVIRAL IN A DENGUE CHALLENGE MODEL For personal use only Administer ISLA-101 daily Phase II trial protocol Up to 4 cohorts/4 arms Incl

  10. Slide 10: World Class Team in Place

    WORLD CLASS TEAM IN PLACE TEAM ASSEMBLED WITH DOMAIN EXPERTISE IN CLINICAL TRIALS AND MANUFACTURING For personal use only Sponsor Key Island people overseeing the ISLA-101 PEACH study Teresa Byrne, Vice President Kevin Swiss, CMC Consultant Clinical Product Development. Regulatory CMC expert, Overse

  11. Slide 11: Upcoming Milestones

    UPCOMING MILESTONES For personal use only H1 FY 2022 H2 FY 2022 H1 FY 2023 H2 FY 2023 (July-Dec 2021) (Jan-June 2022) (July-Dec 2022) (Jan-June 2023)  New drug product  Clinical material • Open IND  Sign SUNY CTA manufacturer manufactured • Screening,  Announce Principal secured enrolment, dosin

  12. Slide 12: Contact

    For personal use only David Foster Chief Executive Officer & Executive Director dfoster@islandpharmaceuticals.com Authorized for release by Paul MacLeman, Executive Chairman Island Pharmaceuticals Limited ACN 641 183 842 www.islandpharmaceuticals.com Registered office: Suite 201, ISLAND PHARMACEUTIC

Island Pharmaceuticals — Investor Presentation (December 2022) on 6ix